



6 April 2022

Novartis Pharma AG
Basel, Switzerland
CH-4056

Reference: EudraCT 2019-001031-31 Novartis Protocol ID CPTH258BDE01

A comparative Double Masked, Two-Arm, Randomized, Multicenter, Phase IIb Study
analyzing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual
Impairment due to Diabetic Macular Edema (BUZZARD)

Trial 2019-001031-31 was cancelled with no patient enrollment and as such, no
results will be reported.